Kairos Pharma, Ltd. (KAPA)
| Market Cap | 2.95M -88.8% |
| Revenue (ttm) | n/a |
| Net Income | -5.81M |
| EPS | -1.95 |
| Shares Out | 3.39M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,098,858 |
| Open | 1.1100 |
| Previous Close | 1.1500 |
| Day's Range | 0.8700 - 1.1200 |
| 52-Week Range | 0.8480 - 9.5900 |
| Beta | 1.45 |
| Analysts | Buy |
| Price Target | 49.00 (+5,532.18%) |
| Est. Earnings | Nov 13, 2026 |
About KAPA
Kairos Pharma, Ltd., a clinical-stage biopharmaceutical company, develops immunotherapy and cell therapies for the treatment of cancer. The company offers therapeutics, including antibodies and small molecules for the treatment of prostate cancer, lung cancer, breast cancer, and glioblastoma. It also develops ENV 105, an antibody therapeutic that is in a Phase 2 clinical trial for prostate cancer patients resistant to androgen-targeted therapy, as well as in a Phase 1 clinical trial for non-small cell lung cancer. In addition, the company’s pro... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 2 analysts, the average rating for KAPA stock is "Buy." The 12-month stock price target is $49.0, which is an increase of 5,532.18% from the latest price.
News
Kairos Pharma announces interim efficacy data from Phase 2 trial of ENV-105
Kairos Pharma (KAPA) announced positive interim efficacy data from its ongoing Phase 2 clinical trial evaluating ENV-105 in combination with apalutamide in patients with metastatic castration-resistan...
Kairos Pharma Reports Positive, Statistically Significant Interim Efficacy Data from Phase 2 Trial of ENV-105 in Metastatic Prostate Cancer
LOS ANGELES--(BUSINESS WIRE)---- $KAPA--Kairos Pharma, Ltd. (NYSE American: KAPA), a clinical-stage biopharmaceutical company addressing drug resistance in cancer, today announced positive interim eff...
Kairos Pharma to Present and Moderate at Discovery on Target Conference in Boston, MA
LOS ANGELES--(BUSINESS WIRE)---- $KAPA--Kairos Pharma, Ltd. (NYSE American: KAPA), a clinical-stage biopharmaceutical company focused on overcoming cancer drug resistance, announces that Neil Bhowmick...
Kairos Pharma Transcript: H.C. Wainwright 28th Annual Global Investment Conference
CD105 was highlighted as a central driver of drug resistance in cancer, with ENV105 showing promise in reversing resistance and improving outcomes in prostate and lung cancer trials. Strategic collaborations, robust funding, and a multi-center academic consortium support ongoing and future clinical development, with key data readouts expected in 2026–2027.
Kairos Pharma Slides: Investor presentation
Kairos Pharma has posted slides in relation to its latest quarterly earnings report, which was published on September 14, 2026.
Kairos Pharma to Present at the H.C. Wainwright 28th Annual Global Investment Conference
LOS ANGELES--(BUSINESS WIRE)---- $KAPA #HCW--Kairos Pharma, Ltd. (NYSE American: KAPA), a clinical-stage biopharmaceutical company focused on overcoming cancer drug resistance, announces that John Yu,...
Kairos Pharma announces 1-for-7 reverse stock split
Kairos Pharma (KAPA) announced that it will conduct a reverse stock split of its outstanding shares of common stock at a ratio of 1-for-7. The Reverse Stock Split is expected…
Kairos Pharma Announces 1-for-7 Reverse Stock Split
LOS ANGELES--(BUSINESS WIRE)---- $KAPA--Kairos Pharma, Ltd. (NYSE American: KAPA), a clinical-stage biopharmaceutical company focused on overcoming cancer drug resistance, today announced that it will...
Kairos Pharma Quarterly report: Q2 2026
Kairos Pharma has published its Q2 2026 quarterly earnings report on August 12, 2026.
Kairos Pharma announces collaboration with Bayer to enhance XOFIGO
Kairos Pharma (KAPA) announced a strategic collaboration with Bayer (BAYRY) to evaluate Kairos Pharma’s lead antibody ENV-105, a first-in-class CD105/BMP signaling inhibitor, in combination with Bayer...
Kairos Pharma Announces Strategic Collaboration with Bayer to Enhance XOFIGO Activity in Metastatic Prostate Cancer
LOS ANGELES--(BUSINESS WIRE)---- $KAPA #Bayer--Kairos Pharma, Ltd. (NYSE American: KAPA), a clinical-stage biopharmaceutical company focused on overcoming cancer drug resistance, today announced a str...
CEO.CA's Inside the Boardroom: Kairos Pharma Might Change Cancer Treatment Forever
Toronto, Ontario--(Newsfile Corp. - July 15, 2026) - CEO.CA ("CEO.CA"), the leading investor social network in junior resource and venture stocks, shares exclusive updates with CEOs of junior mining e...
Kairos Pharma announces interim safety data from Phase 1 trial of ENV-105
Kairos Pharma (KAPA) announced interim safety data from its ongoing Phase 1 clinical trial evaluating ENV-105 in combination with osimertinib in patients with advanced EGFR-mutated non-small cell lung...
Kairos Pharma Reports Breakthrough Interim Safety Data in Phase 1 Trial of ENV-105 in EGFR-Mutated Lung Cancer Patients — Targeting a $10 Billion Drug Resistance Market
LOS ANGELES--(BUSINESS WIRE)--Kairos Pharma, Ltd. (NYSE American: KAPA), a clinical-stage biopharmaceutical company addressing drug resistance in cancer, today announced compelling interim safety data...
Kairos Pharma Transcript: AGM 2026
The meeting covered director elections, auditor ratification, a reverse stock split, executive compensation, and equity plan amendments. All proposals were approved by stockholders, with final results to be filed with the SEC. Stockholders were invited to submit questions.
Kapa Gold Announces the Results of Its 2026 Annual General Meeting
Vancouver, British Columbia--(Newsfile Corp. - June 19, 2026) - KAPA GOLD INC. (TSXV: KAPA) ("Kapa" or the "Company") is pleased to announce the results of its annual meeting of shareholders held virt...
Kairos Pharma issues letter from CEO that recaps year, details plans for 2026
Kairos Pharma (KAPA) provides a mid-year update for 2026 and a look ahead to the rest of the year in a letter to shareholders from CEO John Yu, M.D.: “As…
Kairos Pharma Recaps Important Acquisitions and Details Plans for the Balance of 2026 in Letter to Shareholders
LOS ANGELES--(BUSINESS WIRE)--Kairos Pharma Ltd. (NYSE American: KAPA), a clinical-stage biopharmaceutical company focused on innovative cancer therapeutics, provides a mid-year update for 2026 and a ...
Kairos Pharma Proxy statement: Proxy filing
Kairos Pharma filed a proxy statement on May 26, 2026, providing details for shareholder voting and corporate governance matters.
Kairos Pharma Proxy statement: Proxy filing
Kairos Pharma filed a proxy statement on May 22, 2026, providing details for shareholder voting and corporate governance matters.
Kairos Pharma Transcript: 16th Annual LD Micro Invitational Conference
Multiple clinical programs are advancing, including ENV-105 for drug-resistant cancers and KROS-741 for EGFR therapy resistance, supported by strong non-dilutive funding and strategic partnerships. Key clinical and collaboration milestones are expected in 2026, with a focus on rapid trial execution through academic consortia.
Kairos Pharma Slides: Investor presentation
Kairos Pharma has posted slides in relation to its latest quarterly earnings report, which was published on May 15, 2026.
Kairos Pharma Receives GHP Magazine's Healthcare & Pharmaceutical Award
LOS ANGELES--(BUSINESS WIRE)--Kairos Pharma Ltd. (NYSE American: KAPA), a clinical-stage biopharmaceutical company focused on innovative cancer therapeutics, announces that it has been named a winner ...
Kairos Pharma Quarterly report: Q1 2026
Kairos Pharma has published its Q1 2026 quarterly earnings report on May 13, 2026.
Kairos Pharma, Ltd. to Present at the LD Micro Invitational XVI
Los Angeles, California--(Newsfile Corp. - May 13, 2026) - Kairos Pharma, Ltd. (NYSE American: KAPA) announced today that it will be participating in the 16th Annual LD Micro Invitational at the Luxe ...